Who is sponsoring NCT03975192?

NCT03975192 is sponsored by Medical College of Wisconsin.

What drugs are being tested in NCT03975192?

Interventions in NCT03975192: Percutaneous Electrical Nerve Field Stimulation.

What condition does NCT03975192 study?

NCT03975192 studies Opiate Withdrawal Syndrome.

Is NCT03975192 still recruiting?

NCT03975192 is currently withdrawn. Last updated 26 October 2020.

Last reviewed 2020-10-26 · How we verify

NCT03975192: NOW

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neurostimulation for Opiate Withdrawal in the PICU

Withdrawn NA Last updated 26 October 2020

What this trial tests

NA trial testing Percutaneous Electrical Nerve Field Stimulation in Opiate Withdrawal Syndrome. Withdrawn.

Timeline

1 September 2019

Primary endpoint
22 October 2020

22 October 2020

Quick facts

Lead sponsor	Medical College of Wisconsin
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Start date	1 September 2019
Primary completion	22 October 2020
Estimated completion	22 October 2020
Sites	1 location across United States

Drugs / interventions tested

Percutaneous Electrical Nerve Field Stimulation

Conditions studied

Opiate Withdrawal Syndrome — all drugs for Opiate Withdrawal Syndrome →

Sponsor

Medical College of Wisconsin

Who can join

Adults 5 to 17, any sex, with Opiate Withdrawal Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective pilot study to investigate the effects of Percutaneous Electrical Nerve Field Stimulation (PENFS) on symptoms of opioid withdrawal in pediatric patients in the intensive care unit.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Opiate Withdrawal Syndrome

Currently open trials in the same condition.

NCT05995535 — Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal · Phase 2 · recruiting

Other Medical College of Wisconsin trials

Trials by the same sponsor.

NCT07260552 — Rapid Engagement for Solutions to Population and Outcomes Through Networked Dialogue for Coronary Heart Disease · not yet recruiting
NCT06795360 — Weight Changes After Incretin-mimetics · NA · not yet recruiting
NCT07228208 — Role of Endothelial Dysfunction on Exercise Pressor Reflex in Type 2 Diabetes · NA · not yet recruiting
NCT07298460 — Stimulation-based Therapy to Improve Balance in DCM · Phase 1, PHASE2 · not yet recruiting
NCT07434544 — Cardiometabolic Effects of Non-Nutritive Sweeteners (NNS) in Type 1 Diabetes (T1D) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03975192 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical College of Wisconsin
Last refreshed: 26 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03975192.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing